Compared with oxytocin, the combination of ergometrine–oxytocin was associated with a small reduction in the risk of PPH (blood loss >500 ml). There were no statistical
differences between the groups with administration of 5 or 10 IU of oxytocin and blood loss >1000 ml. Adverse effects such as nausea,vomiting, and hypertension were more
associated with the use of ergometrine–oxytocin Considering the heterogeneity among
the trials, there were no statistically significant differences in other maternal
and neonatal outcomes